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Background and purpose: Comorbidity in myasthenia gravis (MG) is important for
diagnosis, treatment and prognosis. Disease complexity was assessed by examining
total drug treatment, immune therapy and comorbidity in a complete national MG
cohort.
Methods: All recipients of the MG-speciﬁc drug pyridostigmine 2004–2010 regis-
tered in the compulsory Norwegian Prescription Database who met the inclusion
criteria were included. The pyridostigmine group was compared with the general
Norwegian population.
Results: Myasthenia gravis patients received co-medication more often than the
controls for nearly all groups of medication, including insulins (95% conﬁdence
interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives
(1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8).
Conclusions: Myasthenia gravis patients are more often treated with non-MG pre-
scription drugs than controls, reﬂecting frequent co-medication and comorbidity.
Introduction
Autoimmune myasthenia gravis (MG) is mainly
caused by the destruction of acetylcholine receptors
by autoantibodies at the neuromuscular junction. MG
is a heterogeneous disease with several subtypes and
autoantibodies against skeletal muscles [1]. Life expec-
tancy for MG patients is now near normal [2], but
management of a ﬂuctuating disease remains challeng-
ing. New therapeutic options are emerging, and MG
subtype classiﬁcation has implications for treatment
strategies [3].
The task of controlling symptoms whilst minimizing
adverse eﬀects of long-term immunosuppressive treat-
ment is intricate. Furthermore, the clinical implica-
tions of heart muscle antibodies, involvement of
respiratory function in MG and use of drugs that may
worsen neuromuscular blockade have not been widely
studied, nor have autoimmune comorbidity and psy-
chiatric disorders been described in unselected MG
cohorts. Our study provides a national cohort for
evaluating the total drug management of symptomatic
MG, oﬀering a new insight into the total disease bur-
den for this group.
The aims of the study were to evaluate drug treat-
ment and thereby also comorbidity in patients with
MG. First, an overview is given of the overall
national drug consumption amongst MG patients.
Secondly, MG autoimmune comorbidity is assessed
through co-medication. Thirdly, psychiatric disorders
in MG are explored through speciﬁc drug treatment.
Fourthly, prescription practice is investigated with
regard to selected drugs considered as relatively con-
traindicated in MG. Finally, ﬁrst- and second-line
drug treatment of MG is investigated.
Methods
Registration of all prescription drugs dispensed from
Norwegian pharmacies in the Norwegian Prescription
Database (NorPD) has been mandatory since 2004,
covering the entire Norwegian population (5 096 300).
A unique personal identiﬁer enables consecutive moni-
toring of individuals in the health system over their
entire life span. The speciﬁc diagnosis or indication
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for the prescription is not registered in NorPD, but
the International Classiﬁcation of Diseases, 10th revi-
sion (ICD-10), and/or the International Classiﬁcation
of Primary Care, 2nd edition (ICPC-2), have been
recorded since 2008. Medication for chronic diseases
such as MG is reimbursed. The reimbursement codes
together with the ICD-10 and ICPC-2 codes function
as a proxy of diagnosis. The following variables were
studied: the patient’s year of birth and sex, the pre-
scriber’s medical speciality, reimbursement codes,
ICD-10/ICPC-2 codes, name of the drug, Anatomical
Therapeutic Chemical (ATC) code, date of expedition
at the pharmacy, and the deﬁned daily dose (DDD)
of the drugs dispensed. In NorPD, the DDD corre-
sponds to the assumed mean maintenance dose of the
drug used per day for its main indication in adults [4].
About 890 individuals with at least one prescription
of pyridostigmine from 1 January 2004 to 30 April
2010 were identiﬁed. Amongst these, 830 (93%) met
one or more of the criteria preset by us to conﬁrm a
diagnosis of MG and were regarded as having MG:
(i) ≥2 prescriptions of pyridostigmine during the study
period; (ii) pyridostigmine prescription made by a
neurologist; (iii) pyridostigmine prescription with
reimbursement code (§13) or ICD-10 code (G70.0)/
ICPC-2 code (N99) speciﬁc for MG (Fig. 1). Final
inclusion for this study was done from the date when
one or more of the criteria were fulﬁlled. Sensitivity
analyses with more stringent inclusion criteria to test
the robustness of our study population were per-
formed (Table S1).
For each subgroup of patients categorized by age
and sex, drug statistics for the corresponding age and
sex groups in the Norwegian population registered in
NorPD from the same period functioned as controls
(Table 1). Total drug treatment of MG patients was
assessed by investigating every prescription dispensed
in all main ATC groups during the study period.
Comparisons of age- and sex-speciﬁc drug use
amongst MG patients and controls were done by cal-
culating the standardized incidence ratio (SIR), i.e.
the observed number of prescriptions for all main
ATC groups divided by the estimated number of pre-
scriptions for the same drug groups dispensed to a
similar group, with regard to age and sex, in the gen-
eral population. Patient age was deﬁned as age at 1
July 2004. The SIR was computed, with 95% conﬁ-
dence interval (CI), assuming a Poisson distribution.
The ATC group ‘Various’ was considered non-speciﬁc
and was excluded from the analyses.
When exploring comorbidities and contraindicated
medications, the following groups of drugs were
included: drugs used in diabetes, insulins and
analogues, thyroid hormones, antipsychotics, anxiolyt-
ics, hypnotics and sedatives, antidepressants, antiepi-
leptics, beta-blocking agents, calcium-channel
blockers, lipid-modifying agents and aminoglycoside
antibacterials. The following groups of immunomo-
dulating agents were assessed: prednisolone, selective
immunosuppressants, tumor necrosis factor alpha
inhibitors, interleukin inhibitors, calcineurin inhibi-
tors, and other immunosuppressants.
To detect any diﬀerences in prescription of ATC
groups related to age and sex, linear regressions were
performed, estimating the mean diﬀerence and 95%
CIs. Two-sided P values ≤ 0.05 were considered
Recipients of pyridostigmine 
1 January 2004 – 30 April 2010: 
890 
Excluded*: 
60 (7%)
MG study population: 
830  
MG women:
527 (63%)
MG men: 
303 (37%)
Figure 1 Selection of the MG study cohort. *Recipients of pyri-
dostigmine who did not meet the inclusion criteria during the
study period.
Table 1 Demographic characteristics of the study population and
population controls, year 2004
MG patients
(n = 830)
Population controls
(n = 4 577 457)
Age (mean)a 57 39
Sex (n, %)
Female 527 (64) 2 269 049 (50)
Male 303 (37) 2 308 408 (50)
Age group (n, %)
0–9 3 (0.4) 598 503 (13)
10–19 29 (4) 591 853 (13)
20–29 36 (4) 570 889 (13)
30–39 105 (13) 698 413 (15)
40–49 97 (12) 639 053 (14)
50–59 148 (18) 595 423 (13)
60–69 159 (19) 374 975 (8)
70–79 175 (21) 299 162 (7)
80–89 67 (8) 180 640 (4)
> 90 11 (1) 28 546 (0.6)
aPatient age was calculated from year of birth and deﬁned as age at
1 July 2004.
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statistically signiﬁcant. The median DDD prescribed
each year was compared for pyridostigmine and for
each of the following immunomodulating agents:
prednisolone, azathioprine, mycophenolic acid, cyclo-
sporine and methotrexate, as recommended by the
European Federation of Neurological Societies guide-
lines for MG treatment [5]. Non-parametric tests were
performed for comparisons regarding amount dis-
pensed between age and sex groups. IBM SPSS Statis-
tics for Windows, version 20.0 (IBM Corp., Armonk,
NY, USA), and Microsoft Excel were used in all sta-
tistical analyses. Ethics committee approval is not
required for studies using anonymous data retrieved
from central health registers.
Results
In total, 87 556 prescription medications were dis-
pensed to the 830 MG patients during the registration
period (Table 2). The mean number of new ATC
groups per year is shown in Table S2. Only 19 individu-
als (2.3%) received no other medication than pyrido-
stigmine. MG patients more often received nearly all
types of medication compared with the control group,
most pronounced for the following treatment groups:
alimentary tract and metabolism (A); systemic hor-
monal preparations, excluding sex hormones and insu-
lins (H); antineoplastic and immunomodulating agents
(L). Patients <50 years received fewer ATC groups than
patients ≥50 years and women received fewer than
men, but neither of the diﬀerences was signiﬁcant.
Insulins were almost three times more frequently
prescribed to MG patients (95% CI 2.0–3.7, Table 3)
compared with controls. This was observed for MG
patients ≥50 years (1.9–3.7), for men (1.7–4.3) and for
women (1.7–4.0). MG patients <50 years also had
increased prescriptions of insulins (SIR = 2.8), but
there were too few users to provide suﬃcient statisti-
cal power (N = 5). A hundred and ten MG patients
(13%) received a prescription of thyroid hormones.
Thyroid hormones were prescribed about four times
more frequently to MG patients <50 years (2.4–5.5)
and male MG patients (2.3–5.0). Patients ≥50 years
and female MG patients received thyroid hormones
about twice as often compared with controls (1.5–2.2
and 1.4–2.2, respectively).
In all, 29% of MG patients received treatment with
hypnotics and sedatives, and such drugs were twice as
often given to MG patients than to controls for the
age group <50 years (1.2–2.3). 21% received antide-
pressants, twice as often given to male MG patients
than to male controls (1.3–2.2). For the remaining age
and sex groups, slightly more MG patients than con-
trols were treated with hypnotics, sedatives and an-
tidepressants. 20% received anxiolytics, whilst 7%
received antipsychotics (Table 3). Anxiolytics and
antipsychotics were prescribed to MG patients and
controls with the same frequency.
Myasthenia gravis patients were twice as often trea-
ted with antiepileptic drugs (1.7–2.5). They were also
more frequently treated with calcium-channel blockers
(1.2–1.7) and lipid-modifying agents (1.1–1.4), but
with the same frequency as in the controls with beta-
blocking agents (0.9–1.2). All four drug groups were
given more frequently to MG patients <50 years
compared with controls at the same age (Table 3).
However, the number of users of calcium-channel
blockers, lipid-modifying agents and beta-blocking
agents was too low to provide enough statistical
power (N = 6, 11, 11 respectively).
The DDDs of pyridostigmine were signiﬁcantly
lower for MG patients <50 years compared with those
≥50 years (P < 0.001). There was no diﬀerence
between men and women (P = 0.8). Immunomodulat-
ing agents were prescribed less to patients <50 years
(P < 0.001) and women (P = 0.001) compared with
patients ≥50 years and men (Table 4); 406 MG
patients (49%) had no immunomodulating agents
expedited during the study period. The mean number
of new groups of immunomodulating agents used per
year was not signiﬁcantly diﬀerent between the two
age and sex groups (P = 0.2 and P = 0.9, respectively;
Fig. 2a and b). Regression analyses with mutual
adjustment for age and sex did not alter the diﬀer-
ences regarding age and sex.
Signiﬁcantly fewer DDDs of prednisolone was pre-
scribed to patients <50 years compared with patients
≥50 years (P < 0.001). No age diﬀerence was seen for
azathioprine (P = 0.1). Women were prescribed signif-
icantly fewer DDDs of prednisolone (P < 0.001) and
azathioprine (P = 0.002) than men. For mycophenolic
acid, cyclosporine and methotrexate, the number of
users and DDDs prescribed were too small to be
included in the calculations.
Discussion
This is the ﬁrst study to assess the total drug man-
agement and comorbidity of MG in a complete
national cohort. Our ﬁndings show that co-medica-
tion in MG is widespread, requiring more frequent
drug treatment for several major disease groups than
in the general population. Treatment for diabetes,
thyroid disease and psychiatric disorders in MG is
common, as well as co-medication relatively contrain-
dicated in MG. These ﬁndings demonstrate the exten-
sive disease burden of MG and the complexity of the
disease.
© 2014 The Author(s)
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Increased treatment frequency with drugs for the
cardiovascular system in MG patients younger than
50 years was found. Arguably, there is a risk of
ascertainment bias as MG patients more regularly
visit a physician. However, physical inactivity due to
muscle weakness, side eﬀects of steroid treatment
such as weight gain and elevated blood glucose levels
are factors that may contribute to the increased risk
of cardiovascular disease, even in younger individu-
als. The possibility for cardiac involvement in MG is
also well recognized [6], although death caused by
cardiac diseases is not increased [2]. The clinical
implications remain unclear [7], but our data strongly
indicate that there is a clinically relevant association
between MG and cardiovascular disease. Early treat-
ment of airway infections in MG patients is recom-
mended [3], and may account for the increased use of
anti-infectives. Immunosuppressed patients are also
in general more prone to infections [5].
In this study, thyroid hormones were most fre-
quently prescribed to MG patients <50 years and to
men compared with controls. A recent systematic
review estimated concomitant autoimmune diseases in
MG at 13%, with thyroid disease as the most fre-
quent [8]. In prospectively identiﬁed MG patients,
type 1 and 2 diabetes was found in 10% and 8%,
respectively [9]. All antidiabetics in our study were
most frequently prescribed to patients ≥50 years. In
addition to the general autoimmune disease overlap,
reduced physical activity, corticosteroid treatment as
well as other comorbid conditions may serve as
catalysts for acquired metabolic syndrome and type 2
diabetes.
Use of antidepressants was more frequent amongst
MG patients than controls. The frequency of patients
receiving antidepressants in our study is in good
agreement with previous reports of aﬀective disorders
in MG [10]. Drug treatment of anxiety and sleep dis-
turbances was lower in our study compared with pre-
vious reports [11,12]. Psychiatric symptoms can mimic
MG symptoms, but may also be under-recognized due
to overlapping symptoms [13].
Age ≥50 years and male sex were predictors for
immunosuppressive treatment in our study. Immuno-
suppressive drugs and thymectomy represent the main
principles in treating moderate to severe MG [3], often
lifelong in late-onset and thymoma cases (15% of MG
patients). Complete stable remission can be induced in
early-onset cases after thymectomy. The beneﬁt of thy-
mectomy for MG symptom relief is questionable for
late-onset MG and thymoma MG patients [14]. Only
56% of the patients in our study over 50 years were
treated with immunoactive drugs. Some muscle weak-
ness is probably under-recognized in older patients due
to the aging process or concomitant illness. One recent
hospital-based study reported immunosuppressive ther-
apy in 65% of late-onset cases [15]. In our study early-
and late-onset cases were combined in the group above
50 years. A biological explanation implicating diﬀer-
ences in disease severity is possible, but inadequate
immunosuppression in our patients is also highly prob-
able. Teratogenic and other adverse eﬀects inﬂuence
immunosuppressive treatment in young females. Such
drugs are rarely used in pregnancy [16].
Only 6% of all MG patients in our study had such
a severe disease that second-line immunomodulating
drugs were required, indicating that prednisolone and
azathioprine alone or in combination are suﬃcient for
symptom control in nearly all MG patients. NorPD
does not provide information on other treatment
modalities, such as thymectomy, plasma exchange and
intravenous administration of immunoglobulins.
Patients identiﬁed with severe MG were predomi-
nantly ≥50 years old and females. MuSK-MG is more
often seen in females and is associated with more
severe disease, but this MG subtype is very rare in
Norway [17]. Information on MG subtypes is not
available in the NorPD.
The main strength of our study is case ascertain-
ment from one single, unbiased, comprehensive
Table 4 Number of MG patients using selected immunomodulating drugs with comparisons of DDDs prescribed, 2004–2010
Women
(n = 527)
Men
(n = 303)
<50 years
(n = 270)
≥50 years
(n = 560)
ATC group  Drug n (%) n (%) P valuea n (%) n (%) P valuea
H02AB06  Prednisolone 220 (42) 167 (55) <0.001 102 (38) 285 (51) 0.001
L04AX01  Azathioprine 109 (21) 92 (30) 0.002 56 (21) 145 (26) 0.12
L04AA06  Mycophenolic acid 16 (3) 7 (2) NA 8 (3) 15 (3) NA
L04AD01  Cyclosporine 11 (2) 4 (1) NA 7 (3) 8 (0.1) NA
L04AX03  Methotrexate 9 (2) 1 (0.3) NA 3 (0.1) 7 (0.1) NA
All immunosuppressants 246 (47) 178 (59) 0.001 113 (42) 311 (56) <0.001
NA, not available or insuﬃcient data available for analysis. aNon-parametric tests were used to calculate the diﬀerence in median deﬁned daily
dose between sex and age groups in the period 2004–2010.
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database with a full, national population as controls.
96% of the entire Norwegian population has been
included in NorPD since its establishment in 2004
with at least one prescription drug dispensed from a
pharmacy. The 1 year prevalence of 68%–69% of the
population in NorPD has proven stable [18]. Identi-
fying MG patients by prescriptions of pyridostigmine
is considered sensitive with a high positive predictive
value for the diagnosis [19–21], and with good agree-
ment of calculated prevalence rates using pyridostig-
mine prescriptions registered in the NorPD compared
with rates calculated from a nationwide acetylcholine
receptor antibody database [22]. Amongst 67 patients
treated at our department for the past 30 years, only
three did not receive pyridostigmine (unpublished
data). NorPD did not include indication for prescrip-
tion until 2008. This represents a potential source of
overestimation. The inclusion criteria used in this
study secured high sensitivity, although speciﬁcity
may be lower. However, sensitivity analyses with
more stringent criteria did not alter the basic charac-
teristics of the MG cohort. Moreover, nearly 90% of
our study population had conﬁrmed at least one
MG-reimbursed prescription of pyridostigmine or
from a neurologist. Only MG patients with a con-
ﬁrmed diagnosis are given reimbursement. The reim-
bursement code is therefore highly speciﬁc for MG.
Pyridostigmine is not prescribed on a regular basis to
any other disease groups. The rare disease Lam-
bertEaton myasthenic syndrome, with a prevalence
of 2–3 per million [23], is treated with pyridostigmine
and reimbursement would be given as for MG. Six
patients with pyridostigmine were identiﬁed with an
additional prescription of ﬂudrocortisone, the stan-
dard drug for treating orthostatic hypotension, and
may marginally bias our ﬁndings.
This study reveals the true complexity of MG and
contributes to an understanding of the impact of MG
on health. Awareness of comorbidities and knowledge
of treatment practice should help physicians in choos-
ing the best treatment strategy.
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Figure 2 (a) Mean number of new groups of immunomodulat-
ing agents used in MG patients (%) below and above
50 years of age after MG diagnosis per year, 2004–2010. Open
bars, patients <50 years; hatched bars, patients ≥50 years. (b)
Mean number of new groups of immunomodulating agents
used in MG men and women (%) after MG diagnosis per
year, 2004–2010. Open bars, men; hatched bars, women.
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Table S1. Characteristics of the study population with
diﬀerent inclusion criteria.
Table S2. Mean (SD) number of new ATC groups for
830 MG patients per year, 2004–2010.
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